Xi Cui
Lanzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.
Journal: RMD open
Published: January 04, 2026
Targeting ERK1/2 attenuates neutrophil extracellular traps-mediated pro-inflammatory and pro-fibrotic effects in myositis-associated interstitial lung disease.
Journal: Rheumatology (Oxford, England)
Published: October 26, 2025
Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition.
Journal: RMD open
Published: October 14, 2025
Baricitinib alleviates myositis-associated interstitial lung disease in mice by inhibiting the NETs-cGAS-STING-EMT axis.
Journal: International immunopharmacology
Published: May 01, 2025
Interleukin-33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK-Mediated Epithelial-Mesenchymal Transition: ERK as a Potential Therapeutic Target.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 16, 2025
Neutrophil extracellular traps mediate macrophage polarization and pyroptosis through the TLR9-NF-κB/AIM2 pathway exacerbating myositis-associated interstitial lung disease.
Journal: International immunopharmacology
Published: April 09, 2025
cGAS-STING mediates neutrophil extracellular traps-induced EMT in myositis-associated interstitial lung disease: STING as a potential therapeutic target.
Journal: International immunopharmacology
Published: October 31, 2024
Pirfenidone alleviates interstitial lung disease in mice by inhibiting neutrophil extracellular trap formation and NLRP3 inflammasome activation.
Journal: Clinical and experimental immunology
Published: October 20, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026